この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2022/5/121 分で読めます
Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments." The topic to be discussed is the financial transparency and efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →